The patient sought care for a mass in her right buttock, but had no tonsillar symptoms.
Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor that most commonly affects the head, neck, and trunk. However, a new case report highlights an extremely rare situation: tonsillar metastasis.
According to study authors, only about 100 cases of metastases to the palatine tonsil have been reported in scientific literature. Of those, only 5 reported cases have been metastatic MCC.
“Among the reported cases of metastatic MCC to the palatine tonsil, patients commonly presented with pharyngitis, dysphagia, and other oropharyngeal symptoms, years after wide excision of the primary cutaneous tumor,” they wrote in Clinical Case Reports.
The patient that is the subject of the new report was a 57-year-old woman who complained of a soft tissue mass in her right buttock that had been enlarging for 3 years. The mass measured 12 cm x 8 cm on physical examination, and so investigators performed a biopsy. The biopsy specimen was positive for cytokeratin 20, chromogranin, epithelial membrane antigen, and Merkel cell polyomavirus. It was negative for thyroid transcription factor-1 and cytokeratin 7. Based on those findings, the patient received a diagnosis of MCC. However, supplemental screening revealed something else.
“At our institution, fused fluorodeoxyglucose-18 positron emission tomography (PET)-CT scan noted asymmetric uptake involving the left tonsil region, concerning for neoplasm versus an inflammatory process,” the authors wrote.
The patient had not reported any symptoms in her tonsil area, and there was no palpable cervical or supraclavicular lymphadenopathy.
Surgery was planned, and physicians considered performing a preoperative tonsillar biopsy, but the patient’s care team decided against the procedure due to the risk of bleeding and sampling error. Instead, they followed consensus recommendations and removed the left tonsil and the right-buttock tumor. They also carried out a lymphadenectomy.
The patient was discharged after a 4-day inpatient stay and treated with a 1-year course of adjuvant avelumab (Bavencio) at a dose of 800 mg every 2 weeks. Over time, her Merkel cell polyomavirus titers decreased. As of the case report’s writing, the patient was 11 months out from her initial diagnosis without any evidence or progression.
The report authors concluded by discussing the rarity of this patient’s situation.
“Metastatic tonsillar tumors are uncommon due to the fact that the tonsil lacks afferent lymphatic vessels and histologically consists of mainly reticuloendothelial cells with strong ability to clear tumor,” they wrote.
The investigators said it is likely that the dissemination of the malignancy to the tonsil occurred via a hematogenous route.
They noted that the development of MCC is associated with Merkel cell polyomavirus in about 8 of 10 cases, and with chronic UV-mediated damage in the remaining 20% of cases. Patients with elevated Merkel cell polyomavirus oncoprotein antibody titers tend to have favorable outcomes, they said, “and when detectable, the oncoprotein antibody titer can serve as a tumor marker indicative of overall MCC burden.”
However, the investigators said Merkel cell polyomavirus status is not predictive of immunotherapy response. Instead, they said it is believed that efficacy is tied to tumor mutational burden.
“This current report is the first to present an asymptomatic, synchronous case of metastatic MCC to the tonsil,” they said. “Due to the natural history of this tumor, aggressive multimodal treatment is crucial.”
Reference
Okonkwo PC, Henning A, Plaza J, Agrawal A, Contreras CM. A rare tonsillar metastasis of Merkel cell carcinoma: a case report. Clin Case Rep. Published online March 19, 2023. doi:10.1002/ccr3.7063
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More